Cargando…
Prostate-selective α antagonists increase fracture risk in prostate cancer patients with and without a history of androgen deprivation therapy: a nationwide population-based study
INTRODUCTIONS: Prostate-selective α antagonists are recommended for relief of lower urinary tract symptoms in prostate cancer patients despite uncertainty of fracture risk as an addition to androgen deprivation therapy (ADT). The purpose of this study is to estimate fracture risk associated with the...
Autores principales: | Kao, Wei-Heng, Kuo, Chang-Fu, Chou, I-Jun, See, Lai-Chu, Huang, Wen-Kuan, Chiou, Meng-Jiun, Zhang, Weiya, Doherty, Michael, Wang, Chun-Chieh, Hsu, Jun-Te, Chen, Hsien-Hsin, Hong, Ji-Hong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5797048/ https://www.ncbi.nlm.nih.gov/pubmed/29435177 http://dx.doi.org/10.18632/oncotarget.23828 |
Ejemplares similares
-
CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer
por: Hwang, Justin H., et al.
Publicado: (2019) -
Androgen deprivation therapy for prostate cancer and the risk of hematologic disorders
por: Liu, Jui-Ming, et al.
Publicado: (2020) -
Association between Androgen Deprivation Therapy and Risk of Dementia in Men with Prostate Cancer
por: Liu, Jui-Ming, et al.
Publicado: (2021) -
Type of Androgen Deprivation Therapy and Risk of Dementia Among Patients With Prostate Cancer in Taiwan
por: Huang, Wen-Kuan, et al.
Publicado: (2020) -
The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment
por: Ku, Ja Yoon, et al.
Publicado: (2015)